8082-737-676
Kalkine 0
countryflagUK
L

0R15 7172.0 -4.284% 0R1E 10080.0 -3.263% 0M69 None None% 0R2V 206.0 -8.2814% 0QYR 1608.0 -7.4266% 0QYP 374.2 -2.1699% 0RUK None None% 0RYA 1551.0 -2.2684% 0RIH 156.5 -0.5402% 0RIH 152.0 -2.8754% 0R1O 180.2 9265.9044% 0R1O None None% 0QFP 10450.0 107.3413% 0M2Z 279.7562 -0.1879% 0VSO 44.63 25.3476% 0R1I None None% 0QZI 587.0 0.8591% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 158.85 -6.9129%
0R15 7172.0 -4.284% 0R1E 10080.0 -3.263% 0M69 None None% 0R2V 206.0 -8.2814% 0QYR 1608.0 -7.4266% 0QYP 374.2 -2.1699% 0RUK None None% 0RYA 1551.0 -2.2684% 0RIH 156.5 -0.5402% 0RIH 152.0 -2.8754% 0R1O 180.2 9265.9044% 0R1O None None% 0QFP 10450.0 107.3413% 0M2Z 279.7562 -0.1879% 0VSO 44.63 25.3476% 0R1I None None% 0QZI 587.0 0.8591% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 158.85 -6.9129%

Henry Schein Inc

Healthcare US HSIC

67.2USD
-2.05(2.96%)

Last update at 2025-04-03T16:45:00Z

Day Range

66.1269.22
LowHigh

52 Week Range

60.0182.63
LowHigh

Fundamentals

  • Previous Close 69.25
  • Market Cap9110.83M
  • Volume394474
  • P/E Ratio24.12
  • Dividend Yield-%
  • EBITDA934.00M
  • Revenue TTM12451.00M
  • Revenue Per Share TTM95.81
  • Gross Profit TTM 3831.00M
  • Diluted EPS TTM2.95

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-310M1000M2000M3000M4000M5000M6000M7000M8000M9000M10000M11000M12000M13000M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M1000M2000M3000M4000M5000M6000M7000M8000M9000M10000M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-300M-250M-200M-150M-100M-50M0M50M100M150M200M250M300M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31590M600M610M620M630M640M650M660M670M680M690M700M710M

Dividends Paid

2018-12-312019-12-312020-12-312021-12-312022-12-31-140M-120M-100M-80M-60M-40M-20M0M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 721.00M 830.55M 499.89M 680.31M 695.35M
Minority interest 28.00M 29.29M 15.63M -24.77000M 26.25M
Net income 538.00M 631.23M 403.79M 520.79M 535.88M
Selling general administrative 2771.00M 2812.66M 2246.95M 2357.92M 2217.27M
Selling and marketing expenses - - - - -
Gross profit 3831.00M 3672.25M 2814.34M 3090.89M 3595.08M
Reconciled depreciation 212.00M 209.53M 185.54M 184.94M 207.56M
Ebit 747.00M 851.66M 535.30M 718.26M 914.29M
Ebitda 1108.00M 1075.62M 758.90M 930.75M 1121.85M
Depreciation and amortization 361.00M 223.96M 223.60M 212.49M 207.56M
Non operating income net other 33.00M 33.82M 19.89M 217.51M 43.35M
Operating income 747.00M 851.66M 535.30M 718.26M 753.05M
Other operating expenses 11769.00M 11541.43M 9551.75M 9252.84M 12308.79M
Interest expense 44.00M 27.60M 41.38M 50.79M 78.79M
Tax provision 170.00M 197.35M 95.37M 159.51M 155.49M
Interest income 17.00M 6.45M 9.84M 15.76M 21.24M
Net interest income -27.00000M -21.14900M -31.53500M -35.03500M -57.55000M
Extraordinary items - - - -5.95700M 116.84M
Non recurring - 7.94M 32.09M 14.71M 101.40M
Other items - - - - -
Income tax expense 170.00M 197.35M 95.37M 159.51M 155.49M
Total revenue 12647.00M 12401.02M 10119.14M 9985.80M 13202.00M
Total operating expenses 2953.00M 2812.66M 2246.95M 2357.92M 2701.88M
Cost of revenue 8816.00M 8728.77M 7304.80M 6894.92M 9606.91M
Total other income expense net -26.00000M -21.10800M -35.40800M -37.95400M -140.31000M
Discontinued operations - - 0.99M -6.32300M 105.16M
Net income from continuing ops 566.00M 660.53M 418.44M 725.46M 539.86M
Net income applicable to common shares 538.00M 631.23M 403.79M 694.73M 535.88M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10573.00M 8607.00M 8481.09M 7772.53M 7151.10M
Intangible assets 916.00M 587.00M 667.63M 479.43M 572.88M
Earning assets - - - - -
Other current assets 639.00M 466.00M 413.10M 432.94M 445.36M
Total liab 5420.00M 3936.00M 4417.90M 3788.15M 3520.96M
Total stockholder equity 3655.00M 3446.00M 3425.13M 3348.17M 2998.04M
Deferred long term liab - 36.00M 42.28M 30.07M 64.99M
Other current liab 1080.00M 1038.00M 1115.02M 1029.53M 958.93M
Common stock 1.00M 1.00M 1.37M 1.43M 1.43M
Capital stock 1.00M 1.00M 1.37M 1.43M 1.43M
Retained earnings 3860.00M 3678.00M 3595.23M 3454.83M 3116.22M
Other liab - 397.00M 418.95M 422.85M 396.16M
Good will 3875.00M 2893.00M 2854.15M 2504.39M 2462.49M
Other assets - 232.00M 190.41M 149.41M 120.81M
Cash 171.00M 117.00M 117.97M 421.19M 106.10M
Cash and equivalents - - - - -
Total current liabilities 2683.00M 2224.00M 2306.51M 2283.10M 2038.37M
Current deferred revenue 89.00M - - - 64.99M
Net debt 2570.00M 1380.00M 1098.72M 581.23M 892.25M
Short term debt 494.00M 182.00M 137.56M 247.92M 199.17M
Short long term debt 414.00M 109.00M 61.17M 183.20M 133.82M
Short long term debt total 2741.00M 1497.00M 1216.68M 1002.42M 998.35M
Other stockholder equity - -233.00000M 1.37M 1054.31M 47.77M
Property plant equipment - 667.00M 366.46M 342.00M 329.64M
Total current assets 4488.00M 3988.00M 3844.03M 3791.41M 3226.50M
Long term investments 180.00M 472.00M 423.87M 366.44M 327.92M
Net tangible assets - 542.00M 516.66M 692.05M 249.93M
Short term investments - - - - -
Net receivables 1863.00M 1442.00M 1451.83M 1424.79M 1246.25M
Long term debt 1937.00M 1040.00M 811.35M 515.77M 622.91M
Inventory 1815.00M 1963.00M 1861.14M 1512.50M 1428.80M
Accounts payable 1020.00M 1004.00M 1053.93M 1005.65M 880.27M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - 649.00M 638.07M 636.21M 632.09M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -206.00000M -233.00000M -171.47800M -108.08400M -167.37300M
Additional paid in capital - - - - -
Common stock total equity - 1.00M 1.37M 1.43M 1.43M
Preferred stock total equity - - - - -
Retained earnings total equity - 3678.00M 3595.23M 3454.83M 3116.22M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 209.00M 223.00M -34.60700M 154.47M -23.62500M
Deferred long term asset charges - - - - -
Non current assets total 6085.00M 4619.00M 4637.06M 3981.12M 3924.60M
Capital lease obligations 390.00M 348.00M 344.17M 303.44M 241.62M
Long term debt total - 1040.00M 811.35M 515.77M 622.91M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 11.00M 5.67M 12.78M 323.96M -24.70000M
Change to liabilities -96.00000M 84.71M 224.27M 160.85M 241.65M
Total cashflows from investing activities -276.00000M -677.21700M -115.01900M -424.37300M -192.95400M
Net borrowings 259.00M 161.43M -68.99300M -1188.50600M 297.20M
Total cash from financing activities -315.00000M -332.95700M -187.18500M -215.98000M -603.77600M
Change to operating activities -52.00000M 9.06M -6.47900M -57.29100M -165.64500M
Net income 566.00M 660.53M 419.42M 719.14M 562.13M
Change in cash -1.00000M -303.22000M 315.09M 49.21M -94.44900M
Begin period cash flow 118.00M 421.19M 106.10M 56.88M 174.66M
End period cash flow 117.00M 117.97M 421.19M 106.10M 80.21M
Total cash from operating activities 602.00M 709.58M 598.91M 654.09M 684.71M
Issuance of capital stock - 0.00000M - 361.09M -
Depreciation 212.00M 209.53M 185.54M 184.94M 207.56M
Other cashflows from investing activities -191.00000M -603.86900M -78.96700M -672.11800M -77.61700M
Dividends paid - - - -148.14600M 17.52M
Change to inventory -126.00000M -295.13100M -31.81700M 14.70M -84.78400M
Change to account receivables -7.00000M 4.16M -189.34900M -72.68900M -147.49900M
Sale purchase of stock -485.00000M -401.21100M -73.78900M -525.00000M -200.00000M
Other cashflows from financing activities 229.00M 208.93M 497.82M 1284.93M -375.73400M
Change to netincome 93.00M 38.67M 23.19M -303.83000M 8.37M
Capital expenditures 96.00M 79.02M 48.83M 76.22M 90.64M
Change receivables -7.00000M 4.16M -189.34900M -72.68900M -147.49900M
Cash flows other operating -40.00000M 7.11M 387.08M 670.11M -102.70900M
Exchange rate changes - - - - 17.57M
Cash and cash equivalents changes 11.00M -300.59400M 296.71M 13.73M -94.44900M
Change in working capital -281.00000M -197.20100M -3.37200M 45.57M -82.69600M
Stock based compensation 54.00M 78.42M 8.79M 44.92M 36.24M
Other non cash items 112.00M -28.75600M 66.39M -338.37000M 13.34M
Free cash flow 506.00M 630.57M 550.08M 577.87M 594.07M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HSIC
Henry Schein Inc		 -2.05 2.96% 67.20 24.12 14.04 0.74 2.50 0.95 13.33
MCK
McKesson Corporation		 20.96 3.02% 714.49 17.95 14.53 0.20 5.04 0.22 12.17
COR
Cencora Inc.		 7.80 2.79% 287.31 23.39 - - -
CAH
Cardinal Health Inc		 -2.55 1.84% 136.12 166.11 14.71 0.12 16.07 0.12 19.78
SHPMF
Shanghai Pharmaceuticals Holding Co. Ltd		 - -% 1.56 7.71 5.45 0.03 0.57 0.03 0.88

Reports Covered

Stock Research & News

View All

Profile

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Henry Schein Inc

135 Duryea Road, Melville, NY, United States, 11747

Key Executives

Name Title Year Born
Mr. Stanley M. Bergman Exec. Chairman & CEO 1950
Mr. James P. Breslawski Exec. Vice Chairman & Pres 1954
Mr. Steven Paladino Exec. Director 1957
Mr. Mark E. Mlotek Exec. VP, Chief Strategic Officer & Exec. Director 1956
Mr. Ronald N. South Sr. VP & CFO 1962
Mr. Michael Saul Ettinger Exec. VP & COO 1961
Ms. Olga Timoshkina VP of Corp. Fin., Chief Accounting Officer & Corp. Controller NA
Mr. Christopher Pendergast Sr. VP & CTO 1964
Graham Stanley VP of Investor Relations & Strategic Fin. Project Officer NA
Mr. Walter Siegel Sr. VP & Chief Legal Officer 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions